Back to discover
Drug

Sugammadex sodium

Approved · FDA / EMA
Emerging researchLate-stage development

Also known as Bridion, Sugammadex, sugammadex (as sodium), sugammadex (sodium).

RxNorm1726987
2
Research papers
13
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: SUGAMMADEX SODIUM (ANDA214126)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX SODIUM (ANDA214230)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX SODIUM (ANDA214306)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX SODIUM (ANDA215575)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX SODIUM (ANDA218727)

Regulatory2026-07-28FDA

Approval: SUGAMMADEX SODIUM (ANDA218728)

Regulatory2026-07-28FDA

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial

Clinical trial2025-03-20Results posted · ClinicalTrials.gov

A Double-blind, Randomized, Parallel Design Study to Compare Postoperative Recovery Between the Sugammadex Group and the Neostigmine Group in Patients After COVID-19.

Clinical trial2024-12-25Primary completion · ClinicalTrials.gov

Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

Clinical trial2022-09-08Completed · ClinicalTrials.gov

A Double-blind, Randomized and Controlled Multicenter Prospective Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

Clinical trial2021-07-12Results posted · ClinicalTrials.gov

Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.

Research2010-10-01European journal of anaesthesiology

Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.

Research2009-08-27Anesthesia and analgesia

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sugammadex sodium
Aliases & brands
BridionSugammadexsugammadex (as sodium)sugammadex (sodium)
RxNorm CUI
1726987
Regulatory jurisdictions
emafda

Regulatory timeline

13 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2021-11-15
Latest approval
2026-07-28
Authorities
FDA · EMA
Total events
13
fdaU.S. Food and Drug Administration· 8 events
2026-07-28Approval
Approval: SUGAMMADEX SODIUM (ANDA218728)
Evidence ↗
2026-07-28Approval
Approval: SUGAMMADEX SODIUM (ANDA218727)
Evidence ↗
2026-07-28Approval
Approval: SUGAMMADEX SODIUM (ANDA218814)
Evidence ↗
emaEuropean Medicines Agency· 5 events
2023-06-23Approval
Approval: Sugammadex Piramal (EMA)
Indication: Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium… Show full indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

Evidence ↗
2023-05-26Approval
Approval: Sugammadex Adroiq (EMA)
Indication: Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium… Show full indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evidence ↗
2023-01-10Approval
Approval: Sugammadex Amomed (EMA)
Indication: Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced… Show full indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in paediatric patients from birth to 17 years.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

5 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
5
registered trials across all phases
LATEST COMPLETION 2022
5
Late-stage (III+)
4
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 5
Phase 31Phase 43Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Double-blind, Randomized, Parallel Design Study to Compare Postoperative Recovery Between the Sugammadex Group and the Neostigmine Group in Patients After COVID-19.

Unknown statusPH IVKorea University Ansan Hospitaln=3002024

Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

CompletedPH IVZhejiang Cancer Hospitaln=342022

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial

CompletedPH IVUniversity Health Network, Toronton=1202021

A Double-blind, Randomized and Controlled Multicenter Prospective Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

CompletedPH IIIKorea University Anam Hospitaln=1962020

Recent completions

Trials that read out recently, adding to the completed evidence base.

Department of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences（Zhejiang Cancer Hospital), Research Center for Neuro-Oncology Interaction , Institute of Basic Medicine and Cancer, Chinese Academy of Sciences

CompletedPH IVZhejiang Cancer Hospitaln=342022

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial

CompletedPH IVUniversity Health Network, Toronton=1202021

A Double-blind, Randomized and Controlled Multicenter Prospective Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient

CompletedPH IIIKorea University Anam Hospitaln=1962020

Comparison Between the Efficacy of Neostigmine Versus Sugammadex Reversal of Rocuronium Induced Neuromuscular Blockade In Paediatric Patients.

CompletedN/AUniversiti Sains Malaysian=802016

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes1
Neuromuscular Blockade1
Journals, researchers & institutions
Top journals
  • Anesthesia and analgesia1
  • European journal of anaesthesiology1
Leading researchers
  • Alvarez-Gómez JA1
  • Blobner M1
  • Della Rocca G1
  • Eriksson LI1
  • Khuenl-Brady KS1
  • Lora-Tamayo JI1
  • Motsch J1
  • Prins ME1
Leading institutions
free-text, unnormalised
  • Klinik für Anästhesiologie der Technischen Universität München1
  • Medical University Innsbruck1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Sugammadex

Frequently co-studied with Sugammadex sodium in the research literature.

2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.